New Drugs: Roflumilast Cream 0.3% for Psoriasis
Dr. Ted Rosen details the FDA’s recent approval of roflumilast cream 0.3% for treatment of plaque psoriasis, including intertriginous psoriasis. By Ted Rosen, MD, FAADEditor-in-Chief On July 29, 2022, the FDA approved roflumilast cream 0.3% (Zoryve, Arcutis Biotherapeutics) for the treatment of plaque psoriasis, including intertriginous psoriasis, in adults and adolescents 12 years of age […]